Quote:

---

"Amarantus spent $11.2 million in cash and stock to acquire this product. Based on the market capitalization as of November 7, 2014 of $64 million (~800 million shares x $0.08 per share), that’s nearly 20% of the market value now assigned to a brand new asset. In order to fund the future clinical development of ESS, along with existing products like LymPro, Eltoprazine, and MANF, shareholders will see significant dilution. For example, we estimate the cost of the Phase 2a ESS study will be in the area of $4 to $6 million. "

---